Statements (11)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
pharmaceutical drug
|
| gptkbp:activeDuring |
gptkb:parathyroid_hormone
|
| gptkbp:clinicalTrials |
Phase 3
|
| gptkbp:date |
FDA_approved
|
| gptkbp:developedBy |
gptkb:OPKO_Health,_Inc.
|
| gptkbp:formulation |
oral tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
OPKO 4400
|
| gptkbp:mandates |
secondary hyperparathyroidism in patients with chronic kidney disease
|
| gptkbp:marketedAs |
brand_name_RAYALDEE
|
| gptkbp:route |
oral
|
| gptkbp:usedFor |
treatment of hypoparathyroidism
|